Purple Biotech Stock Current Liabilities
| PPBT Stock | USD 0.51 0.01 1.26% |
Purple Biotech fundamentals help investors to digest information that contributes to Purple Biotech's financial success or failures. It also enables traders to predict the movement of Purple Stock. The fundamental analysis module provides a way to measure Purple Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Purple Biotech stock.
Non Current Liabilities Total is likely to gain to about 3 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 3.7 M in 2024. Purple | Current Liabilities |
Purple Biotech Company Current Liabilities Analysis
Purple Biotech's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Purple Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Purple Biotech is extremely important. It helps to project a fair market value of Purple Stock properly, considering its historical fundamentals such as Current Liabilities. Since Purple Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Purple Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Purple Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Purple Current Liabilities Historical Pattern
Today, most investors in Purple Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Purple Biotech's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Purple Biotech current liabilities as a starting point in their analysis.
Purple Biotech Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Purple Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Purple Biotech has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Purple Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Purple Biotech's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Purple Biotech could also be used in its relative valuation, which is a method of valuing Purple Biotech by comparing valuation metrics of similar companies.Purple Biotech is currently under evaluation in current liabilities category among related companies.
Purple Fundamentals
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 120.48 M | ||||
| Shares Outstanding | 26.11 M | ||||
| Shares Owned By Insiders | 3.80 % | ||||
| Shares Owned By Institutions | 8.28 % | ||||
| Number Of Shares Shorted | 297.21 K | ||||
| Price To Book | 0.47 X | ||||
| Price To Sales | 58.08 X | ||||
| Gross Profit | (120 K) | ||||
| EBITDA | (22.07 M) | ||||
| Net Income | (19.88 M) | ||||
| Cash And Equivalents | 36.02 M | ||||
| Cash Per Share | 2.00 X | ||||
| Total Debt | 351 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.94 X | ||||
| Book Value Per Share | 0.14 X | ||||
| Cash Flow From Operations | (19.23 M) | ||||
| Short Ratio | 1.30 X | ||||
| Earnings Per Share | (0.90) X | ||||
| Target Price | 9.67 | ||||
| Number Of Employees | 20 | ||||
| Beta | 0.57 | ||||
| Market Capitalization | 13.59 M | ||||
| Total Asset | 44.3 M | ||||
| Retained Earnings | (137.45 M) | ||||
| Working Capital | 8.61 M | ||||
| Net Asset | 44.3 M |
About Purple Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Purple Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Purple Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Purple Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Purple Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Purple Biotech's short interest history, or implied volatility extrapolated from Purple Biotech options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Purple Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Purple Biotech Piotroski F Score and Purple Biotech Altman Z Score analysis. For more information on how to buy Purple Stock please use our How to Invest in Purple Biotech guide.Note that the Purple Biotech information on this page should be used as a complementary analysis to other Purple Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Purple Stock analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Purple Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Purple Biotech. If investors know Purple will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Purple Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Return On Assets (0.28) | Return On Equity (0.49) |
The market value of Purple Biotech is measured differently than its book value, which is the value of Purple that is recorded on the company's balance sheet. Investors also form their own opinion of Purple Biotech's value that differs from its market value or its book value, called intrinsic value, which is Purple Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Purple Biotech's market value can be influenced by many factors that don't directly affect Purple Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Purple Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Purple Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Purple Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.